Prognostic value of thymidine phosphorylase immunostaining in patients with uterine cervical cancer treated concurrently with doxifluridine, radiotherapy and immunotherapy

• Published in: Oncology reports Vol. 8; no. 2; p. 239
• Main Authors: Sato, S, Yajima, A, Sasaki, H, Mizutani, K, Honjo, H, Yamamoto, K, Ozaki, M, Hasegawa, K, Kudo, T, Yakushiji, M, Hatae, M, Noda, K
• Format: Journal Article
• Language: English
• Published: Greece 01-03-2001
• Subjects: Adjuvants, Immunologic - therapeutic use; Antimetabolites, Antineoplastic - therapeutic use; Biomarkers, Tumor - analysis; Combined Modality Therapy; Female; Floxuridine - therapeutic use; Humans; Immunotherapy; Middle Aged; Neoplasm Staging; Prognosis; Retrospective Studies; Sizofiran - therapeutic use; Stromal Cells - pathology; Survival Rate; Thymidine Phosphorylase - analysis; Time Factors; Uterine Neoplasms - mortality; Uterine Neoplasms - pathology; Uterine Neoplasms - radiotherapy; Uterine Neoplasms - therapy
• ISSN: 1021-335X
• DOI: 10.3892/or.8.2.239

Thymidine phosphorylase (dThdPase) is reportedly identical to platelet-derived endothelial cell growth factor (PD-ECGF). We conducted immunohistochemical staining of dThdPase to assess correlation between its expression in cancer tissue and efficacy of a combination therapy with 5'-DFUR, radiotherapy and sizofilan (SPG) in uterine cervical cancer patients. No difference in response rates was observed between dThdPase positive and negative tumor and stromal cells. Survival curves significantly differed between stromal dThdPase positive and negative groups (p=0.032). Results showed that dThdPase immunostaining is possibly prognostic and predictive in determining success of the combination therapy.